Gilead Sciences, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $29.44B | $28.75B | $27.12B | $27.28B | $27.31B | $24.69B | $22.45B | $22.13B |
| Cost of Revenue | $6.23B | $6.25B | $6.50B | $5.66B | $6.60B | $4.57B | $4.68B | $4.85B |
| Gross Profit | $23.21B | $22.50B | $20.62B | $21.62B | $20.70B | $20.12B | $17.77B | $17.27B |
| Gross Margin | 78.8% | 78.3% | 76.0% | 79.3% | 75.8% | 81.5% | 79.2% | 78.1% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | $9.11B | $5.02B |
| SG&A Expense | $5.77B | $6.09B | $6.09B | $5.67B | $5.25B | $5.15B | $4.38B | $4.06B |
| Operating Income | $10.02B | $1.66B | $7.61B | $7.33B | $9.92B | $4.07B | $4.29B | $8.20B |
| Operating Margin | 34.0% | 5.8% | 28.0% | 26.9% | 36.3% | 16.5% | 19.1% | 37.1% |
| Interest Expense | — | — | $944.0M | $935.0M | $1.00B | $984.0M | $995.0M | $1.08B |
| Pretax Income | $9.80B | $690.0M | $6.86B | $5.81B | $8.28B | $1.67B | $5.16B | $7.80B |
| Income Tax Expense | $1.29B | $211.0M | $1.25B | $1.25B | $2.08B | $1.58B | $-204.0M | $2.34B |
| Net Income | $8.51B | $480.0M | $5.67B | $4.59B | $6.23B | $123.0M | $5.39B | $5.46B |
| Net Margin | 28.9% | 1.7% | 20.9% | 16.8% | 22.8% | 0.5% | 24.0% | 24.7% |
| EPS (Basic) | $6.84 | $0.38 | $4.54 | $3.66 | $4.96 | $0.10 | $4.24 | $4.20 |
| EPS (Diluted) | $6.78 | $0.38 | $4.50 | $3.64 | $4.93 | $0.10 | $4.22 | $4.17 |
| Shares Outstanding (Basic) | 1.24B | 1.25B | 1.25B | 1.26B | 1.26B | 1.26B | 1.27B | 1.30B |
| Shares Outstanding (Diluted) | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.26B | 1.28B | 1.31B |
| Dividends Per Share | $3.16 | $3.08 | $3.00 | $2.92 | $2.84 | $2.72 | $2.52 | $2.28 |